Bernard Pluta Appointed as President of Recipharm’s Development Services

Recipharm has appointed Bernard Pluta to lead its new global development...
Recipharm has appointed Bernard Pluta to lead its new global development organization. Source: Recipharm

Sweden-based drug developer and toll manufacturer Recipharm has appointed Bernard Pluta to lead its new global development organization, which is to be implemented during the first half of 2018 and will comprise a total of 400 employees across six countries.

The scientific, chemical and pharmaceutical expertise will cover end-to-end development services, ranging from development of active compounds to providing dossiers for marketing authorization applications in all major geographies.

Pluta is currently general manager of Recipharm’s manufacturing and development operations in Pessac, France and recently led a group-wide project focusing on optimizing and coordinating the company’s development capacities in Sweden, Italy, France, US, India and Israel.

Before joining Recipharm in 2015, he ran his own CMO consultancy business and held executive positions at Theramex, Merck Serono and Teva. Pluta holds a dual degree as industrial engineer and MBA. In his new role, he will report to CEO Thomas Eldered and become a member of the group’s management team. Pluta

He will continue as general manager of Recipharm in Pessac until a successor has been appointed.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.